Therapeutic management of hyperlipoproteinemia (a)

Kosmas, Constantine E.; Sourlas, Andreas; Mallarkey, Gordon; Silverio, Delia; Ynoa, Domingo Y; Montan, Peter D; Guzman, Eliscer; García, Mario J.

doi:10.7573/dic.212609

Cited by 16 publications

(22 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are no specific treatments for Lp(a) level reduction and the most effective and promising ones are still at the stage of clinical trials [9]. Specific Lp(a) apheresis and LDL apheresis have demonstrated the stabilization, and even the regression, of atherosclerotic plaques in the coronary and carotid arteries as well as a significant reduction in the risk of adverse cardiovascular events [10,11].…”

Section: Introductionmentioning

confidence: 99%

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis

Афанасьева

Filatova

Arefieva

et al. 2021

JCDD

View full text Add to dashboard Cite

Background and aims: Chronic inflammation associated with the uncontrolled activation of innate and acquired immunity plays a fundamental role in all stages of atherogenesis. Monocytes are a heterogeneous population and each subset contributes differently to the inflammatory process. A high level of lipoprotein(a) (Lp(a)) is a proven cardiovascular risk factor. The aim of the study was to investigate the association between the increased concentration of Lp(a) and monocyte subpopulations in patients with a different severity of coronary atherosclerosis. Methods: 150 patients (124 males) with a median age of 60 years undergoing a coronary angiography were enrolled. Lipids, Lp(a), autoantibodies, blood cell counts and monocyte subpopulations (classical, intermediate, non-classical) were analyzed. Results: The patients were divided into two groups depending on the Lp(a) concentration: normal Lp(a) < 30 mg/dL (n = 82) and hyperLp(a) ≥ 30 mg/dL (n = 68). Patients of both groups were comparable by risk factors, autoantibody levels and blood cell counts. In patients with hyperlipoproteinemia(a) the content (absolute and relative) of non-classical monocytes was higher (71.0 (56.6; 105.7) vs. 62.2 (45.7; 82.4) 103/mL and 17.7 (13.0; 23.3) vs. 15.1 (11.4; 19.4) %, respectively, p < 0.05). The association of the relative content of non-classical monocytes with the Lp(a) concentration retained a statistical significance when adjusted for gender and age (r = 0.18, p = 0.03). The severity of coronary atherosclerosis was associated with the Lp(a) concentration as well as the relative and absolute (p < 0.05) content of classical monocytes. The high content of non-classical monocytes (OR = 3.5, 95% CI 1.2–10.8) as well as intermediate monocytes (OR = 8.7, 2.5–30.6) in patients with hyperlipoproteinemia(a) were associated with triple-vessel coronary disease compared with patients with a normal Lp(a) level and a low content of monocytes. Conclusion: Hyperlipoproteinemia(a) and a decreased quantity of classical monocytes were associated with the severity of coronary atherosclerosis. The expansion of CD16+ monocytes (intermediate and non-classical) in the presence of hyperlipoproteinemia(a) significantly increased the risk of triple-vessel coronary disease.

show abstract

Section: Introductionmentioning

confidence: 99%

The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis

Афанасьева

Filatova

Arefieva

et al. 2021

JCDD

View full text Add to dashboard Cite

show abstract

“…The type II coronary intervention study has shown that lowering serum cholesterol and LDL-C and increasing HDL-C by drug intervention retarded the progress of CAD [10].…”

Section: Discussionmentioning

confidence: 99%

A Comparative Study on Clinical Evaluation of the Hypolipidemic Effects of Allium sativum, Trigonella foenum-graecum, Commiphora mukul, Picrorhiza kurroa, and Piper nigrum: A Pilot Study

Shaikh¹,

Ali²,

Mohsin³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundCardiovascular disease is a leading cause of morbidity and mortality. Therefore, it is essential to prevent cardiovascular diseases by correcting modifiable risk factors such as lowering lipid levels, lowering blood pressure, improving eating habits, giving up smoking, etc. The present study assessed the efficacy of herbal preparation containing Allium sativum (A. sativum), Commiphora mukul (C. mukul), and Trigonella foenum-graecum (T. foenum-graecum) in patients with hyperlipidemia. MethodologyPatients were given extracts of A. sativum 350 mg, T. foenum-graecum 350 mg, C. mukul 200 mg, Picrorhiza kurroa (P. kurroa) 200 mg, and Piper nigrum (P. nigrum) 5 mg. Unichem Laboratories, Mumbai, provided placebo tablets similar in shape and size to herbal tablets. Patients were assessed for compliance, and a complete lipid profile was done at DO, D15, D46, D76, and D106. In addition, total cholesterol and highdensity lipoprotein-cholesterol (HDL-C) serum triglyceride were estimated by the respective methods throughout the study. ResultsThe weight of the patients remained stable, the mean weight before being 65.42 ± 8.35 kg and after completion of the study being 65.42 ± 8.35 kg. There were no changes in the ECG during or after the drug therapy in any of the patients. Group A comprised nine patients, and group B had ten patients. Serum creatinine (mg %) was 0.94 and 0.95, fasting blood sugar mg (%) was 111.05 and 99.63, and postprandial blood sugar (mg %) was 150.89 and 147.94 on pre-treatment and post-treatment, respectively. The mean serum triglyceride levels in group

show abstract

“…Overall, the risk of developing type 2 diabetes was found to be higher in patients with Lp[a] values in the highest compared to the lowest quintile (hazard ratio, 1.28; 95% CI, 1.14-1.43). Since cardiovascular disease remains the leading cause of death and disability worldwide [21,22], even in aging populations [23], the therapeutic management of hyperLp[a] shall hence be regarded as a valuable option for lowering the clinical, societal and economic burden of cardiovascular disorders [24].…”

Section: Lipoprotein[a] and Cardiovascular Diseasementioning

confidence: 99%